Atara and Pierre Fabre Resubmitted Ebvallo to FDA

The companies have filed for approval of the cell therapy after resolving previous manufacturing and trial concerns.

Updated on Sept. 30, 2026 in Cancer

Bold flat-color editorial illustration of a glass medical vial, representing a clinical therapy submission in the pharmaceutical regulatory process. — Atara Biotherapeutics and Pierre Fabre have resubmitted their cell therapy, Ebvallo, to the FDA for approval following the resolution of previous clinical and manufacturing concerns. AI Illustration. Upload story photo >

Live Poll

Do you trust the FDA's current process for approving new medical treatments?

Pierre Fabre and Atara Biotherapeutics have officially resubmitted their cell therapy, Ebvallo, for FDA approval. This follows two previous rejections involving manufacturing inspection findings and study design concerns.

Why it matters

The resubmission marks a significant regulatory turning point after the FDA reversed its position on trial design requirements. Successful approval would unlock a $31 million milestone payment for Atara and provide a new treatment option for eligible patients.

The resubmission includes updated data from the Phase 3 ALLELE study and supplemental evidence from expanded access programs. The FDA has confirmed that prior Good Manufacturing Practice (GMP) compliance issues are resolved.

The players

Atara Biotherapeutics

Atara is a biopharmaceutical company specializing in T-cell immunotherapy for cancer and autoimmune conditions.

Pierre Fabre

Pierre Fabre is a French pharmaceutical and cosmetic company that focuses on oncology and dermatology research.

FDA

The Food and Drug Administration is the federal agency responsible for regulating food, drugs, and medical devices in the United States.

The details

The updated application incorporates a larger patient cohort and extended follow-up periods compared to the original submission. The partners also included commercial experience data gathered from usage in Europe to bolster the clinical case.

November 2023: Atara and Pierre Fabre signed a commercialization agreement.
January 2025: Atara announced the second FDA rejection of Ebvallo.
May 2026: The FDA reached an agreement that single-arm studies could be sufficient.
September 2026: The partners resubmitted the BLA to the FDA.
March 29, 2027: Potential FDA target action date for the application.

Health Landscape

This resubmission reflects a broader shift toward greater flexibility in how the FDA evaluates cell therapies for rare conditions. By incorporating supplemental data from European commercial experience, the companies are aligning with evolving regulatory pathways for single-arm trials.

The potential approval of Ebvallo could offer a new therapeutic alternative for patients aged two and older who require this specific cell therapy. Patients should consult with their oncologists to understand how this regulatory process may eventually change their treatment access.

The takeaway

Regulatory processes for novel cell therapies often require multiple iterations before meeting specific agency benchmarks. Patients and stakeholders should monitor the March 2027 target date as the definitive indicator for the therapy's market availability.